topotecan has been researched along with Neuroectodermal Tumors, Primitive, Peripheral in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Adamson, PC; Balis, FM; Berg, SL; Blaney, SM; Bleyer, WA; Gillespie, A; Krailo, MD; Needle, MN; Poplack, DG; Reaman, GH; Sato, JK | 1 |
1 trial(s) available for topotecan and Neuroectodermal Tumors, Primitive, Peripheral
| Article | Year |
|---|---|
Phase II trial of topotecan administered as 72-hour continuous infusion in children with refractory solid tumors: a collaborative Pediatric Branch, National Cancer Institute, and Children's Cancer Group Study.
Topics: Adolescent; Adult; Antineoplastic Agents; Bone Neoplasms; Child; Child, Preschool; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Infant; Infusions, Intravenous; Male; Neoplasms; Neuroblastoma; Neuroectodermal Tumors, Primitive, Peripheral; Osteosarcoma; Rhabdomyosarcoma; Sarcoma, Ewing; Soft Tissue Neoplasms; Topotecan | 1998 |